Science

Marco Donia about the FDA approved nivolumab across solid tumors

Marco Donia/dff.dk

Dec 30, 2024, 00:53

Marco Donia about the FDA approved nivolumab across solid tumors

Marco Donia, Senior Consultant at the University of Copenhagen Herlev Hospital, shared a recent article by Diogo Garcia on LinkedIn:

“Subcutaneous anti-PD-1 (nivolumab) approved across solid tumors by FDA (27 Dec 2024).

Important improvement in logistics, not the first approval of subcutaneous inhibitors of the PD-1/PD-L1 pathway (see potential advantages and disadvantages.

Oral PD-L1 inhibitors in development.”

Title: Subcutaneous Immune Checkpoint Inhibitors: Friends or Foes?

Authors: Diogo Garcia, Julian A. Marin-Acevedo and Bruna Pellini

Marco Donia about the FDA approved nivolumab across solid tumors

Marco Donia is a Senior Consultant, Clinician-Scientist and Junior Research Group Leader (TIL group) at the Department of Oncology and Center for Cancer Immune Therapy, University of Copenhagen Herlev Hospital, Denmark. He serves as an Associate Professor in Clinical Oncology at the University of Copenhagen.

Donia is also a clinical oncologist treating patients with cancer immunotherapy. His research group is currently investigating new immune-regulatory circuits in PD-1/PD-L1 resistant tumors.

More posts featuring Marco Donia.

Bruna Pellini cancer Diogo Garcia FDA Julian A. Marin-Acevedo Marco Donia nivolumab OncoDaily Oncology Oral PD-L1 inhibitors subcutaneous inhibitors tumors

Aladina Foundation was Honored with the Yvonne Humanitarian Award by OncoDaily

Rod Stewart and Prostate Cancer: How He Went Against, How He Survived, and More

Kimryn Rathmell: The year in cancer - 24 advances in 2024

Celebrating the Holiday Magic with Medical Community

Melanie Griffith and Skin Cancer: How She Went Against, How She Survived, and More

Special Coverage